Endothelin in neurohormonal activation in heart failure

被引：3

作者：

Boerrigter, G ^{[1
]}

Burnett, JC ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Cardiorenal Res Lab, Rochester, MN 55905 USA

来源：

CORONARY ARTERY DISEASE | 2003年 / 14卷 / 07期

关键词：

endothelin; endothelin-A receptor; endothelin-B receptor; antagonist; neurohormonal activation; congestive heart failure; endothelin-converting enzyme; atherosclerosis;

D O I：

10.1097/00019501-200311000-00004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：495 / 500

页数：6

共 34 条

[1]

Garlichs CD, 1999, EUR J CLIN INVEST, V29, P12

[2] Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure [J].

Givertz, MM ;

Colucci, WS ;

LeJemtel, TH ;

Gottlieb, SS ;

Hare, JM ;

Slawsky, MT ;

Leier, CV ;

Loh, E ;

Nicklas, JM ;

Lewis, BE .

CIRCULATION, 2000, 101 (25) :2922-2927

[3] Effects of aging and subsequent exercise training on gene expression of endothelin-1 in rat heart [J].

Iemitsu, M ;

Miyauchi, T ;

Maeda, S ;

Tanabe, T ;

Irukayama-Tomobe, Y ;

Goto, K ;

Matsuda, M ;

Yamaguchi, I .

CLINICAL SCIENCE, 2002, 103 :152S-157S

[4] Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat [J].

Iemitsu, M ;

Miyauchi, T ;

Maeda, S ;

Sakai, S ;

Kobayashi, T ;

Fujii, N ;

Miyazaki, H ;

Matsuda, M ;

Yamaguchi, I .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (06) :R2029-R2036

[5] Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [J].

Kalra, PR ;

Moon, JCC ;

Coats, AJS .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) :195-197

[6] Endothelin system: The double-edged sword in health and disease [J].

Kedzierski, RM ;

Yanagisawa, M .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :851-876

[7] EVIDENCE FOR ENDOTHELIN-1-MEDIATED VASOCONSTRICTION IN SEVERE CHRONIC HEART-FAILURE [J].

KIOWSKI, W ;

SUTSCH, G ;

HUNZIKER, P ;

MULLER, P ;

KIM, J ;

OECHSLIN, E ;

SCHMITT, R ;

JONES, R ;

BERTEL, O .

LANCET, 1995, 346 (8977) :732-736

[8] Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure [J].

Krum, H ;

Gu, AG ;

WilshireClement, M ;

SacknerBernstein, J ;

Goldsmith, R ;

Medina, N ;

Yushak, M ;

Miller, M ;

Packer, M .

AMERICAN HEART JOURNAL, 1996, 131 (02) :337-341

[9] CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS [J].

LERMAN, A ;

EDWARDS, BS ;

HALLETT, JW ;

HEUBLEIN, DM ;

SANDBERG, SM ;

BURNETT, JC .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (14) :997-1001

[10] Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 [J].

Louis, A ;

Cleland, JGF ;

Crabbe, S ;

Ford, S ;

Thackray, S ;

Houghton, T ;

Clark, A .

EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) :381-387

← 1 2 3 4 →